The Growth Pillar Finally Shows Up: 3M Accelerates to 3.2% Organic, Stock Jumps 7.7%

Results vs. Consensus

If Q2 was a margin quarter wearing a revenue beat as decoration, Q3 was the reverse: the headline was growth. Adjusted organic sales rose 3.2%, doubling the first-half pace, and management was explicit that roughly 150 bps of the ~150–200 bps of outperformance versus a ~1–2% blended macro came from self-help (commercial excellence plus new-product introduction) rather than a cyclical lift. The GAAP-to-adjusted EPS gap ($1.55 vs. $2.19) again traces to known special items: $0.19 of litigation costs, $0.30 from a loss on the abrasives divestiture, $0.13 from the Solventum stake mark, and $0.02 of transformation charges.

Quality of Beat

• Revenue: High quality, and the most important data point of the quarter. The acceleration was broad (US +~4% vs. +1% in H1, China high-single, Europe back to growth) and self-help-driven. About 20 bps of the 70 bps of second-half improvement was a discrete pavement-marking project pulled from Q4 into Q3, but the underlying 50 bps is durable commercial-excellence and NPI traction.
• Margins: High quality. Adjusted operating margin of 24.7% (+170 bps) extends the productivity story, and year-to-date margin is up 220 bps to 24.2%. The +170 bps is lighter than Q2's +290 bps, but that reflects tougher comps and stranded-cost timing, not a slowdown in the program.
• EPS: Clean. The $2.19 had no obvious one-time flatter this quarter (unlike Q2's $0.06 investment sale); it is operationally sourced, with the third guidance raise of the year confirming the run-rate.

Segment Performance

The acceleration was led by the segment where the commercial-excellence playbook started, exactly the sequencing the bull case predicts. Management cited adjusted margin moves of roughly +200 bps at both Safety & Industrial and Consumer, with Transportation & Electronics down about 20 bps on an adjusted basis as PFAS stranded costs and mix offset volume leverage.

Safety & Industrial

The flagship group grew organically 4.1%, its strongest quarter since 2018 outside the COVID rebound, on broad strength: electrical markets up low teens (data-center construction demand), industrial adhesives and tapes another quarter of mid-single-digit share gains, and both personal safety and abrasives accelerating to mid-single digits. This more than offset known auto-aftermarket weakness and emerging roofing-granules softness from the slow housing market.

"Our focus on commercial and innovation excellence helped SIBG grow 4.1% for the quarter, the highest growth since 2018 ex-COVID." — Anurag Maheshwari, CFO

Assessment: This is the single best validation of the turnaround thesis to date. The segment where self-help was deployed first is now compounding above 4%, with the data-center exposure in electrical markets adding a structural tailwind the company can lean into. If this is the template, the read-through to T&E and Consumer over the next two years is the crux of the growth case.

Transportation & Electronics

The cyclical group's adjusted organic growth accelerated to 3.6% (1.8% GAAP) from 1% in the first half, led by double-digit aerospace, continued electronics momentum (a new mainstream smartphone optically-clear-adhesive and notebook film win), and auto turning flattish after a down first half on spec-in wins, including with Chinese OEMs. Reported segment margin rose to 22.0%, though on an adjusted basis management flagged a ~20 bps decline as PFAS stranded costs weigh here more than anywhere else.

"Transportation and Electronics adjusted sales accelerated from 1% in the first half to 3.6% in Q3... the main drivers of growth were double-digit growth in aerospace, continued momentum in the electronics business and automotive being flattish after a down first half." — Anurag Maheshwari, CFO

Assessment: The acceleration here matters because T&E was the laggard, and the electronics move from premium into mainstream is exactly the kind of share expansion that NPI is supposed to deliver. The margin remains the watch item: until PFAS stranded costs roll off, this group will under-earn its volume.

Consumer

The smallest group again grew 0.3% organically, its fourth consecutive quarter of growth in a soft retail market, on Filtrete, Scotch tape, and Meguiar's demand backed by NPI and advertising investment. Reported segment margin reached 22.2%, up roughly 200 bps, continuing the pattern of productivity-led margin gains on a flat volume base.

"In a relatively weak consumer market, our consumer business has demonstrated the ability to grow 4 quarters in a row, including 0.3% organic growth in each of the last 3 quarters." — Anurag Maheshwari, CFO

Assessment: Consumer remains the segment where the growth thesis is least proven; 0.3% is technically positive but barely. The margin expansion is impressive and real, but Consumer is still being run for profit on flat volume, and a genuine volume inflection here has not yet arrived.

Key Topics & Management Commentary

Overall Management Tone: Confident and increasingly forward-leaning, a step up from the measured posture of Q2. Brown spoke about "bending the curve" on new-product revenue and seeing "more opportunities today than 6, 8 months ago," and for the first time sketched a 2026 framework. The only guarded moment was the personal-injury update, where the language remained deliberately non-committal pending case vetting.

1. The Growth Inflection

The defining development of the quarter was that organic growth accelerated to 3.2% against an unchanged, soft macro, with management quantifying roughly 150 bps of outperformance versus a ~1–2% blended macro and attributing at least 100 bps of it to commercial excellence and NPI. This is the first quarter where the growth pillar moved from promise to proof.

"We accelerated organic revenue growth from 1.5% in the first half to 3.2% in Q3 driven by successful execution of our commercial excellence initiatives and contribution from NPI... which resulted in growth above macro." — Anurag Maheshwari, CFO

Assessment: This recasts the entire investment case. A company that can grow ~150 bps above its end markets via self-help, while expanding margin, is a different and better business than the low-single-digit organic grower the stock was priced as a year ago. The durability question (can it hold above macro through tougher comps?) is now the central debate.

2. New Product Introduction Bending the Revenue Curve

The NPI program produced its clearest revenue evidence yet: five-year new-product sales up 30% in Q3 and 16% year-to-date, tracking to high teens for the full year. 3M launched 70 products in the quarter (196 YTD), now expects to exceed 250 for the year against a 215 target, and has nearly 1,000 ideas in the funnel. R&D directed at new-product development has risen from below 30% to 35–36% of the R&D pool.

"We're beginning to bend the curve on revenue from new products with sales from products launched in the last 5 years up 30% in Q3 and 16% year-to-date, tracking to be up high teens for the full year." — William Brown, Chairman & CEO

Assessment: The leading indicator has become a coincident one. Management was candid that ~80% of launches are incremental "Class 3" line extensions and that the bigger Class 4/5 category-creating products are a 2026–2027 story, so the steepest part of the NPI contribution is still ahead. This is the durable growth engine, and it is finally visible in the numbers.

3. The Third Guidance Raise and the 2026 Framework

3M raised full-year adjusted EPS to $7.95–$8.05 (third raise of the year) and lifted margin-expansion guidance to 180–200 bps. More notably, management offered an early 2026 framework consistent with the February Investor Day: growth above macro, continued margin expansion, operationally-driven EPS growth, and >100% FCF conversion, with formal guidance to come in January.

"We are raising our earnings per share guidance for the year from a range of $7.75 to $8 to a range of $7.95 to $8.05, representing an approximately $0.12 increase at the midpoint or 10% growth for the year." — Anurag Maheshwari, CFO

Assessment: Three raises in three quarters is a credibility-compounding pattern from a management team that started the year deliberately conservative. The early 2026 framework, paired with commentary that the 25%-margin-by-2027 target now looks achievable or pull-forward-able, is the setup for the January print to be the next re-rating catalyst.

4. PFAS Personal Injury: The Bellwether Vacated

The most consequential litigation update: the October personal-injury bellwether trial date was removed by the judge to allow unfiled cases to be filed, with roughly 14,000 cases now filed (each with multiple claims) and in vetting. The PWS settlement ($12.5 billion) is largely behind them with few opt-outs; AG cases continue piecemeal (New Jersey done, Vermont over time, Illinois ~September 2026).

"There was an October trial date for the bellwether. The judge decided to remove that date to allow unfiled cases to be filed... You'll note in the 10-Q that there have been more cases. It's just under 14,000, each case has multiple claims, and we're now in the process of vetting all of that." — William Brown, Chairman & CEO

Assessment: A double-edged update. The near-term binary catalyst that capped the multiple last quarter is gone, which removes a Q4 air-pocket risk. But the case count growing to ~14,000 and the timeline stretching out means the overhang is deferred, not lifted. The market read it as a positive on the day; we read it as the overhang changing shape rather than shrinking.

5. Portfolio Reshaping and the First Divestiture

3M agreed to sell its precision grinding and finishing business (within SIBG abrasives), less than 1% of sales across seven underutilized factories with over a decade of sales declines, booking a $161 million loss but characterizing it as non-dilutive. This is the first concrete action on the ~10% of the 120 profit centers (roughly 2–3% of revenue) management has flagged for potential exit.

"We made progress with an agreement to sell our precision grinding and finishing business within our SIBG abrasive division. While this business is small at less than 1% of company sales, it's been a drag on results with over a decade of sales declines in 7 dedicated underutilized factories." — William Brown, Chairman & CEO

Assessment: Small in dollars but meaningful as a signal: management is executing the portfolio-shaping it described at Investor Day, and doing it on non-dilutive terms. The optionality of trimming ~2–3% of low-quality revenue to lift the composite growth-and-margin profile is a quiet positive that the market is not yet paying for.

6. A New, Longer-Horizon Restructuring

Brown introduced a new enterprise-wide transformation program, distinct from the prior quick-payback restructuring: a multi-year redesign of the manufacturing network, distribution, and business-process services, deliberately staged ("not a big bang") to avoid disrupting growth momentum. The Q3 charge was $14 million, with ~$15 million expected in Q4 and a fuller framing in January.

"This is all about how do you grow and accelerate our margin expansion journey beyond 25% by '27... If anything, I'm seeing more opportunities today than we saw 6, 8 months ago when we had the Investor Day." — William Brown, Chairman & CEO

Assessment: This is the tell that the margin story has a second act beyond the 25%-by-2027 target. A structured, multi-year footprint redesign is precisely the kind of self-help that extends the productivity runway, and management's "more opportunities than I expected" framing is a forward-looking positive, albeit one that is years from full realization.

7. Operational Excellence: OTIF and OEE

On-time-in-full reached 91.6%, up 200 bps sequentially and 300 bps year-on-year, the best in 20-plus years, with four straight months above 90%. Operating equipment effectiveness reached 63% year-to-date (+300 bps), now systematically tracked on 229 assets representing ~60% of production. Cost of quality fell to 5.7% (−150 bps YoY) against a sub-4% target.

"Our on-time and full metric was 91.6% in the quarter... achieving the highest on-time performance we've had in any quarter going back 20-plus years." — William Brown, Chairman & CEO

Assessment: Service has flipped from a growth headwind to a tailwind, and the OEE work is uncovering latent capacity (the Jinshan optical-adhesive line doubling a customer's share is a concrete example). These are the unglamorous operating gains that quietly support both growth and margin, and they remain early in their runway.

8. Capital Deployment

3M returned $900 million in Q3 ($400 million dividends, $500 million buyback), $3.9 billion year-to-date ($1.2 billion dividends, $2.7 billion repurchases). Management reiterated buybacks remain accretive and a continuing use of the >100%-conversion free cash flow.

"We returned $900 million to shareholders in Q3, $400 million in dividends and $500 million of share repurchases. Year-to-date, we returned $3.9 billion to shareholders." — William Brown, Chairman & CEO

Assessment: The capital-return cadence is steady and the FCF that funds it is now comfortably above 100% conversion. With litigation timelines extending rather than spiking, the balance-sheet first-call concern is marginally easier than a quarter ago, supporting continued buyback.

Guidance & Outlook

The implied fourth quarter looks soft on the surface (adjusted EPS below $1.80 versus Q3's $2.19), but management framed this as ordinary Q3-to-Q4 seasonality: roughly $250 million lower volume (consumer back-to-school and industrial timing), Q4 factory shutdowns weighing on absorption, plus a deliberate step-up in growth investment ($175M to $185M for the year, mostly in Q4) and tariffs landing more heavily.

Implied Q4: Year-over-year is the right comparison, where management expects to again grow above macro with ~100 bps of margin expansion at the midpoint and up to ~150 bps at the high end if volume and productivity continue to outperform.

Street at: Consensus moves up with the raise, but the Q4 seasonality means the upgrade is to the EPS base, not to a steeper exit rate.

2026 framework: Growth above macro, continued margin expansion, operationally-led EPS growth, >100% FCF conversion; the $1 billion-over-macro Investor Day target steps up to ~$300 million of contribution in 2026 from ~$100 million in 2025. Formal guidance in January.

Analyst Q&A Highlights

What's Different About This NPI Cycle

The opening line of questioning probed why new-product introduction is finally delivering when every prior 3M CEO had promised it, without a large spending increase. Management attributed it to pace, rigor, and tapping latent internal urgency rather than dollars, with R&D directed at NPI rising from below 30% to 35–36% of the pool.

Q: "Every CEO at 3M has talked about new products, but you seem to be delivering and actually getting results. Without spending a whole heck of a lot more, what do you attribute it to? Have you changed the culture of compensation?"
— Scott Davis, Melius Research

A: "We're tapping into a lot of latent ideas, urgency, desire from the team's product developers... We are moving up a little bit on spend... up by 30 basis points, but it's not substantial. We are shifting more of our R&D dollars towards new product development. A couple of years ago, we dipped below 30%. Now it's running 35%, 36%."
— William Brown, Chairman & CEO

Assessment: The most thesis-relevant exchange on the call. The growth is coming from reallocation and execution rigor, not a spending bet, which makes it both higher-return and more durable. The open question Brown himself raised: whether 3M can move beyond incremental Class 3 extensions back to category-creating products, which would lift the structural growth ceiling above the historical 2–3%.

The Personal-Injury Claim Movement

A recurring investor concern about recent movement in personal-injury claim counts drew out the vacated bellwether and the ~14,000-case figure, with management declining to characterize ultimate exposure pending vetting.

Q: "We've had some questions from investors around the movement in claims recently on personal injury in the last couple of months. Just wondered if you could flesh out anything that you have seen there in your own tracking and what the next steps are on that personal injury front?"
— Julian Mitchell, Barclays

A: "There was an October trial date for the bellwether. The judge decided to remove that date to allow unfiled cases to be filed... It's just under 14,000, each case has multiple claims, and we're now in the process of vetting all of that. And we'll talk to investors through SEC filings in these calls as we go forward."
— William Brown, Chairman & CEO

Assessment: Management answered factually but cannot yet size the liability, which is the honest position. The vacated date removes a near-term shock but the rising case count is a reminder that personal injury remains the one PFAS track without a settlement framework. This is the reason the overhang still caps the multiple.

The More-Than-Seasonal Q4 Step-Down

The sharpest pushback concerned why implied Q4 EPS drops below $1.80 from $2.19, more than typical seasonality. Management defended it as ordinary volume seasonality plus a deliberate Q4-weighted investment and tariff step-up, while reiterating year-over-year above-macro growth.

Q: "You did the $2.19. I think your implied is like less than $1.80 in the fourth quarter. I know there's some seasonality there, but I don't recall that kind of drop... Could you maybe just provide a little more color on why the more than seasonal drop-off from 3Q to 4Q?"
— C. Stephen Tusa, JPMorgan

A: "It's actually quite typical between Q3 and Q4... volume is typically $250 million lower between the quarter because of mainly the consumer back-to-school in the third quarter... We also have factory shutdowns in the fourth quarter... This year, clearly, there is a little bit of a step-up in investments and in tariffs between the third and the fourth quarter."
— Anurag Maheshwari, CFO

Assessment: A satisfactory answer that reframes the optics. The Q4 step-down is seasonality plus intentional reinvestment of the year's outperformance, not a demand fade. The year-over-year framing (+100 to +150 bps margin) is the right lens, and the willingness to spend into Q4 signals confidence rather than caution.

Pulling Forward the 25% Margin Target

An analyst pressed on whether the 25%-by-2027 margin target could be pulled forward given the run-rate. Management stopped short of a pull-forward but confirmed strong progress (180–200 bps this year against the 360 bps needed over three years) and promised a refresh in January.

Q: "You have this long-term margin target, maybe not so long term anymore in terms of 25% by 2027. It feels like if I take the moving parts, 3% growth, 35% incrementals, plus a net productivity piece, you get pretty close to that number in 2026... Maybe you can help us think about those moving pieces and if you can pull forward that target for margins."
— Amit Mehrotra, UBS

A: "What we laid out at Investor Day was that we'll get to 25% by 2027. Last year, we finished at 21.4%. So that means 360 basis points over 3 years. If you look at our guidance this year, it's about 180 to 200 basis points... we actually feel very good about the 25% target... and provide more of a refresh in January."
— Anurag Maheshwari, CFO

Assessment: Management is managing expectations deliberately, declining to pull forward officially while leaving the door wide open. With more than half the three-year margin journey potentially done in year one, the January refresh is the likely venue for a target raise, which is a specific, dateable catalyst.

The Restructuring Journey's Scope

Questioning on the new restructuring effort drew out that this is a multi-year, staged footprint and G&A redesign rather than a one-time program, deliberately not sized today to avoid over-promising.

Q: "I just wonder if you could give us a sense of, is this the beginning of a 2 or 3-year very large project? Have you even really mapped this out yet? And what should we expect as we get into maybe 2026 as it relates to these new restructuring actions?"
— Jeffrey Sprague, Vertical Research

A: "This enterprise-wide restructuring effort... is a more longer-term, more thoughtful redesign of our manufacturing network, our distribution network, our business process services... It will not be a big bang. We'll shape more next quarter... This quarter of $14 million, next quarter it will be in that same range, about $15 million."
— William Brown, Chairman & CEO

Assessment: The measured, un-sized framing is a credibility choice; this team has consistently under-promised and over-delivered, so declining to put a headline number on the program reads as discipline. The substance, a multi-year structural-cost lever layered on top of the existing productivity stream, is incrementally bullish for the out-year margin trajectory.

The Portfolio-Reshaping Envelope

An analyst asked whether the divestiture program could expand beyond the stated 2–3% of revenue toward the broader 10% of profit centers flagged as poor fits.

Q: "That 2%, 3% was kind of part of this 10% of the 120 profit centers umbrella that you thought maybe would be better in the hands of other people. Are you... do you feel like you can execute more towards that 10%? Or are we still in that 2% to 3% kind of envelope?"
— Amit Mehrotra, UBS

A: "We concluded that about 10% of that portfolio are in more commodity areas where they may no longer be a strong fit... We're only going to be selling businesses where there's clear value to shareowners... not every business we're in today will be part of that journey going forward."
— William Brown, Chairman & CEO

Assessment: Management kept the official envelope at 2–3% but the "10% of profit centers" framing signals the eventual ambition is larger. Disciplined, value-tested divestitures of low-growth commodity lines are accretive to the composite profile over time; this is optionality the current valuation does not capture.

What They're NOT Saying

1. No sizing of PFAS personal-injury exposure: With ~14,000 cases now filed and the bellwether vacated, management still offers no range, framework, or reserve commentary. The one unsettled PFAS track remains entirely unquantified.
2. No formal 2026 numbers: The framework is qualitative; actual EPS, organic, and margin figures wait until January. Understandable, but it means the most important re-rating input is still three months out.
3. Restructuring program left unsized: Brown explicitly declined to put a number on the new transformation effort. Disciplined, but it leaves a material future margin lever uncharacterized.
4. The Class 3 mix ceiling: Management acknowledged ~80% of launches are incremental line extensions. The unsaid risk is that an NPI engine skewed to Class 3 lifts growth modestly but does not restore the category-creating innovation that historically defined 3M's premium.
5. Roofing granules and housing: The emerging weakness in roofing granules tied to the slow housing market got a passing mention but no framing of how deep or durable it could be if housing stays frozen.

Market Reaction

• Pre-print setup: MMM closed at $154.78 on October 20, up 19.9% year-to-date but down 1.2% over the prior 30 days and up only 14.8% over the trailing twelve months, having cooled from the July peak. The S&P 500 was up 14.5% YTD. The shares sat mid-range of a $124.75–$160.20 52-week closing band.
• Reaction-day move: The stock gapped to $158.00 (+2.1%), traded as high as $166.82, and closed at $166.64, up 7.7% (+$11.86) on 7.3 million shares, 2.7x the 30-day average. The S&P 500 was flat on the day.

The +7.7% move was a clean reward for the growth surprise, amplified by the lighter pre-print positioning. The organic-growth acceleration to 3.2% was the genuine surprise (the Street modeled ~2%), and the vacated bellwether removed a Q4 risk that some had been discounting. Where July's identical beat-and-raise faded because the stock was priced for perfection, October's was bought because the stock had room. The reaction validates the thesis but also resets the valuation higher, which is the tension at the center of our rating.

Street Perspective

Debate: Is the Growth Acceleration Durable or a Comp/Discrete Fluke?

Bull view: The 3.2% is self-help-driven (commercial excellence + NPI), broad across geographies and segments, and the NPI contribution is only getting started as Class 4/5 products and the $300 million 2026 above-macro step arrive. This is a structurally faster business.

Bear view: Roughly 20 bps was a discrete pavement-marking pull-forward, comps get tougher, and the macro is doing none of the work. A 3% print in a soft macro may not repeat once the easy self-help wins are lapped.

Our take: The bulls have the better case. Stripping the discrete item still leaves ~3% with 100+ bps of attributable self-help, and the leading NPI indicators point up. We would underwrite ~3% durable organic, which is a meaningful upgrade from the 2–3% the stock was priced at, but not the 4–5% the most bullish case requires.

Debate: Does the Vacated Bellwether Help or Hurt?

Bull view: Removing the October trial eliminates a near-term binary shock, gives the company more time to vet and consolidate cases, and keeps litigation cash needs spread and manageable.

Bear view: The case count rising to ~14,000 and the timeline stretching out means a larger, later, still-unsized liability. Deferral is not resolution, and the discount the market applies will persist until there is a settlement framework.

Our take: Both are right, which is why it is a wash for the thesis. The bear point is the binding one: until personal injury has a settlement structure like PWS and Combat Arms did, the multiple carries a litigation discount. The market's day-one positive read overweighted the removed-catalyst relief.

Debate: Has Valuation Run Ahead of the Story?

Bull view: At ~21x a still-rising EPS base, with three guidance raises, a credible path to 25% margins (possibly pull-forward-able in January), and portfolio/restructuring optionality, the multiple is justified for an industrial compounder that has rediscovered growth.

Bear view: 3M has re-rated from ~12x distressed to ~21x in eighteen months. The margin and now the growth story are both in the price; from here the stock needs the bull-case durable-3%-plus to materialize against a litigation tail.

Our take: We lean bear on the stock, bull on the business. The +7.7% pop to ~21x captured the growth re-rating in a single session. The risk/reward for new money is balanced here; the asymmetry returns on a pullback or on the January guide stepping the EPS base materially higher.

Model Update Needed

Valuation framing: At $166.64 against an $8.00 FY25 adjusted EPS midpoint, MMM trades at ~20.8x forward earnings. The upgrade to our durable-organic assumption (from 2–3% toward ~3%) and the visible NPI/margin runway support a higher multiple than we carried at initiation, but the stock has moved with the thesis. Our framework now sees fair value around $165–$175 on the EPS power and structurally faster growth, against roughly $135–$145 downside on an adverse personal-injury development. The skew has improved modestly but remains balanced at the current quote, which keeps us at Hold while explicitly closer to an upgrade.

Thesis Scorecard Post-Earnings

Overall: Thesis strengthened. Two of three bull pillars confirmed and the growth pillar upgraded; the anemic-growth bear point is now challenged. The remaining bear case has narrowed to valuation and the deferred PFAS tail.

Action: Maintain Hold, conviction rising. The business case is increasingly compelling; the stock has moved with it. We want the January 2026 guide or a pullback to turn buyer.